Financing ·
OS Therapies raises $7.2M from warrant exercise inducement, expects up to $12.3M total
OSTXOS Therapies Inc
OS Therapies completed an initial closing of a warrant exercise inducement offer on October 15, 2026, receiving approximately $7.2 million in gross proceeds. Seven accredited investors exercised or pre-funded existing warrants to purchase 5,517,253 shares at a reduced price of $1.30 per share. In exchange, the company issued new warrants exercisable at $1.40 per share. The offer expires on October 30, 2026, with total expected proceeds reaching approximately $12.3 million if all existing warrants are exercised. Funds will support clinical development and regulatory filings for Herlystic in osteosarcoma. OS Therapies is a clinical-stage oncology company developing gene-edited Listeria-based cancer immunotherapies.